Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer
Aurélien Pommier(Centre National de la Recherche Scientifique), Simon T. Barry(AstraZeneca (Singapore)), Bhavika Patel(Mayo Clinic in Arizona), Hayley Campbell(AstraZeneca (United Kingdom)), Neil R. Smith(Institute of Cancer Research), Matthew R. Farren(Cancer Research Horizons), Jeremy Frith(AstraZeneca (United Kingdom)), Shethah Morgan(AstraZeneca (United Kingdom)), Catherine A. Eberlein(AstraZeneca (United Kingdom)), Susan E. Critchlow(AstraZeneca (United Kingdom)), R. Huby(AstraZeneca (United Kingdom)), Mark Wappett(AstraZeneca (United Kingdom)), Paul Smith(AstraZeneca (United Kingdom)), Christopher J. Womack(AstraZeneca (United Kingdom)), Jane Kendrew(AstraZeneca (United Kingdom)), Jane Robertson(Cancer Research UK), Filippos Michopoulos(AstraZeneca (United Kingdom))
Cited by 24
Related Papers
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
|Cancer Research|2013|1.5k
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
|Advanced Drug Delivery Reviews|2016|1.1k
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
|British Journal of Cancer|2018|233